Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma
| العنوان: | Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma |
|---|---|
| المؤلفون: | Hermsen, IGC, Haak, HR, de Krijger, Ronald, Kerkhofs, TMA, Feelders, R.A., de Herder, W.W., Wilmink, H, Smit, JWA, Gelderblom, H, de Miranda, NFCC, van Eijk, R (Ronald), van Eijk, R, van Wezel, T, Morreau, H |
| المساهمون: | Pathology, Internal Medicine, Virology, Cancer Center Amsterdam, Oncology |
| المصدر: | European Journal of Endocrinology, 169, 51-8 European Journal of Endocrinology, 169(1), 51-58. Bioscientifica Ltd European Journal of Endocrinology, 169(1), 51-58 European journal of endocrinology / European Federation of Endocrine Societies, 169(1), 51-58. BioScientifica Ltd. European Journal of Endocrinology, 169, 1, pp. 51-8 |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Antineoplastic Agents, Hormonal, MAP Kinase Signaling System, Endocrinology, Diabetes and Metabolism, DNA Mutational Analysis, medicine.disease_cause, Cohort Studies, Endocrinology, Predictive Value of Tests, Internal medicine, medicine, Adrenocortical Carcinoma, Adrenocortical carcinoma, Humans, Mitotane, Epidermal growth factor receptor, beta Catenin, Aged, Neoplasm Staging, Netherlands, Mutation, Cardiovascular diseases [NCEBP 14], biology, PTEN Phosphohydrolase, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, Adrenal Cortex Neoplasms, ErbB Receptors, Treatment Outcome, biology.protein, Female, KRAS, Signal transduction, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-akt, Immunostaining, medicine.drug, Signal Transduction |
| الوصف: | BackgroundAdrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered the standard first-line therapy with only 30% of the patients showing objective tumour response. Defining predictive factors for response is therefore of clinical importance. The epidermal growth factor receptor (EGFR) has been implicated in the development of one-third of all malignancies. EGFR pathway members in ACC have been investigated, however, without available clinical data and relation to survival.MethodsIn this study, mutation status of EGFR and downstream signalling pathways was evaluated in 47 ACC patients on mitotane using direct sequencing, a TaqMan allele-specific assay and immunohistochemistry. Archival formalin-fixed paraffin-embedded tumour tissue was used for all analyses. Patient data were obtained anonymously, after coupling with the collected tumour tissue.ResultsOne BRAF, two EGFR TK domain (c.2590G>A, p.864A>T) and 11 TP53, but no PIK3CA or KRAS, mutations were found. No relationship was found between mutation status, immunostaining and mitotane response or survival.ConclusionIn conclusion, our data suggest that the role of EGFR tyrosine kinase inhibitors in ACC is limited. Treatment with EGFR monoclonal antibodies on the other hand might be beneficial for a larger group of patients. The possible efficacy of this therapy in ACC should be evaluated in future trials. |
| اللغة: | English |
| تدمد: | 0804-4643 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f60cc82f27326db43a7e2c04d1be841Test https://hdl.handle.net/1887/100829Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8f60cc82f27326db43a7e2c04d1be841 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 08044643 |
|---|